UBS AM
XBIT icon

UBS AM’s XBiotech XBIT Stock Holding History

UBS AM’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,500
Closed -$43.7K – 2725
2025
Q1 		$43.7K Buy
+13,500
New +$46.5K ﹤0.01% 2615
2024
Q4 		– Sell
-253,770
Closed -$1.96M – 2765
2024
Q3 		$1.96M Buy
253,770
+5,500
+2% +$36.1K ﹤0.01% 2047
2024
Q2 		$1.28M Buy
+248,270
New +$1.91M ﹤0.01% 2248
2016
Q4 		– Sell
-13,600
Closed -$183K – 2677
2016
Q3 		$183K Hold
13,600
– – ﹤0.01% 2485
2016
Q2 		$285K Buy
+13,600
New +$196K ﹤0.01% 2249

Other funds holding XBIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM's XBIT Position: Q2 2025 in Review

UBS AM sold out of XBiotech (XBIT) in Q2 2025, closing a stake of 13,500 shares — an estimated $43.7K sold.

UBS AM first reported a position in XBIT in Q2 2016 and held it in 5 quarters. The position peaked at $1.96M in Q3 2024. 53 funds tracked by Wall St. Rank hold XBIT as of Q2 2025.

  • UBS AM reported no remaining XBiotech position as of Q2 2025 after selling out during the quarter.
  • UBS AM sold 13,500 XBiotech shares in Q2 2025, an estimated $43.7K.
  • UBS AM first reported a position in XBiotech in Q2 2016 and held it in 5 quarters.
  • UBS AM's XBiotech position peaked at $1.96M in Q3 2024.
  • 53 funds tracked by Wall St. Rank held XBiotech as of Q2 2025.

Based on UBS AM's 13F filing for Q2 2025, filed 14 Aug 2025.